Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Capecitabine in Advanced HNSCC
NCT02524275Phase 2Terminated
- Sponsor
- University of Nebraska
- Start
- Mar 2015
- Primary completion
- Oct 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, capecitabine in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Nebraska. Started Mar 2015; status: terminated.
02
Drugs
docetaxelcapecitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02524275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524275.